SCHEMBL7945677

SCHEMBL7945677

Cc1cc(C(=O)Nc2ccc(F)c(CNc3cccnc3N)c2)nn1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 5/20 0.47
RAB9A P51151 4/20 0.43
NPC1 O15118 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
KDM4E B2RXH2 2/20 0.43
NR2E1 Q9Y466 2/20 0.43
RORA P35398 1/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
ROCK1 Q13464 1/20 0.40
AURKA O14965 1/20 0.40
AURKB Q96GD4 1/20 0.40
GRM4 Q14833 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
ABL1 P00519 1/20 0.39
LCK P06239 1/20 0.39
CSF1R P07333 1/20 0.39
LYN P07948 1/20 0.39
KIT P10721 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7942291 0.89 BACE1 (0.44) BACE1RAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL7941268 0.86 BACE1 (0.48) BACE1RAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL7942267 0.85 MEN1 (0.46) BACE1RAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL7944814 0.85 BACE1 (0.52) BACE1RAB9ANPC1SMN1; SMN2AURKA
SCHEMBL7941880 0.84 SMN1; SMN2 (0.57) BACE1RAB9ANPC1SMN1; SMN2GAA
SCHEMBL7945350 0.84 BACE1 (0.47) BACE1RAB9ANPC1SMN1; SMN2GAA
SCHEMBL7940383 0.84 BACE1 (0.49) BACE1RAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL7940328 0.84 BACE1 (0.65) BACE1RAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL7943475 0.83 BACE1 (0.47) BACE1RAB9ANPC1SMN1; SMN2AURKA
SCHEMBL7939883 0.83 TP53 (0.55) BACE1RAB9ANPC1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885RAB9A 1287/4885NPC1 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.